Cytomics

CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit

Retrieved on: 
Thursday, August 17, 2023

Singapore, Singapore--(Newsfile Corp. - August 17, 2023) - CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company") announced today it will be presenting at the August 24th, 2023 virtual Investor Summit.

Key Points: 

Singapore, Singapore--(Newsfile Corp. - August 17, 2023) - CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company") announced today it will be presenting at the August 24th, 2023 virtual Investor Summit.

Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

Retrieved on: 
Tuesday, August 1, 2023

SINGAPORE, Aug. 1, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced that the chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology, which is exclusively licensed from the Agency for Science, Technology and Research (A*STAR), has been granted a patent by the China National Intellectual Property Administration (CNIPA).

Key Points: 
  • The Company holds an exclusive, worldwide license, for use in immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.
  • CytoMed's CAR-γδ T cell technology has been developed as an investigational cancer therapy to target NKG2D ligands, a type of stress-induced cancer antigens.
  • The Company's other licensed technology from A*STAR is an induced pluripotent stem cell (iPSC)-based technology to derive a novel synthetic γδ NKT cells for the treatment of various types of cancers.
  • A patent for this proprietary technology has already been granted in Japan, and this asset is under preclinical development.

A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US

Retrieved on: 
Thursday, July 6, 2023

Our CAR-γδ T cell technology has received a US patent as we embark on our first-in-human trial.

Key Points: 
  • Our CAR-γδ T cell technology has received a US patent as we embark on our first-in-human trial.
  • CytoMed holds an exclusive, worldwide license, for use on immunotherapy, including stem cell therapy, until the expiration of the patent covering technology.
  • The Company's other licensed technology from A*STAR is an induced pluripotent stem cell (iPSC)-based technology to derive γδ NKT cells for cancer treatments.
  • A patent for this proprietary technology has already been granted in Japan and this asset is under preclinical development.

Global Flow Cytometry in Oncology Market (2021 to 2031) - Focus on Product Type, Technology, Type of Cancer, Applications, End-users, Country Data and Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 15, 2021

The "Global Flow Cytometry in Oncology Market: Focus on Product Type, Technology, Type of Cancer, Applications, End Users, Country Data, and Competitive Landscape - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Flow Cytometry in Oncology Market: Focus on Product Type, Technology, Type of Cancer, Applications, End Users, Country Data, and Competitive Landscape - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global market for flow cytometry in oncology is predicted to grow at a CAGR of 12.02% over the forecast period 2021-2031.
  • What are the major market drivers, challenges, and opportunities in the global flow cytometry in oncology market?
  • What are the underlying structures resulting in the emerging trends within the global flow cytometry in oncology market?

Thermo Fisher Scientific Launches Novel Flow Cytometer with Imaging Capability

Retrieved on: 
Monday, June 7, 2021

CARLSBAD, Calif., June 7, 2021 /PRNewswire/ --Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the Invitrogen Attune CytPix Flow Cytometer, an imaging-enhanced flow cytometer that combines acoustic focusing flow cytometry technology with a high-speed camera.

Key Points: 
  • CARLSBAD, Calif., June 7, 2021 /PRNewswire/ --Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the Invitrogen Attune CytPix Flow Cytometer, an imaging-enhanced flow cytometer that combines acoustic focusing flow cytometry technology with a high-speed camera.
  • "Previously, gathering cell images and high-performance flow cytometry data required two separate experiments, split samples and additional time correlating cell phenotypes with images," said Valerie Bressler-Hill, vice president and general manager, Protein and Cell Analysis, Thermo Fisher Scientific.
  • "The Attune CytPix combines these workflows to offer imaging enhanced flow cytometry.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion.

Invivoscribe Premieres 12-Color Flow Cytometry Capabilities at their Reference Labs in the US, Europe, and China

Retrieved on: 
Thursday, June 3, 2021

Today Invivoscribe, a global leader in precision diagnostics, announced the launch of a new 12-color multiparametric flow cytometry service in Shanghai, China, the newest reference laboratory in their international LabPMM network.

Key Points: 
  • Today Invivoscribe, a global leader in precision diagnostics, announced the launch of a new 12-color multiparametric flow cytometry service in Shanghai, China, the newest reference laboratory in their international LabPMM network.
  • By providing the combination of 12-color flow cytometry and next-generation sequencing (NGS) MRD capabilities in the US, in Europe, and also in China, Invivoscribe now offers a comprehensive international solution for our pharma partners.
  • Invivoscribes globally standardized network of LabPMM reference laboratories offer best in class NGS assays, gene panels, and bioinformatics software, to complement our new MFC panels.
  • We are very fortunate to have exceptional scientists leading our Flow Cytometry Services, says Tony Lialin, Chief Commercial Officer at Invivoscribe.

Global Flow Cytometry Market (2020 to 2026) - by Technology, Product and Service, Application, End-user and Geography - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 27, 2021

Growing demand for early diagnosis and increasing consciousness regarding the advantages of cell-based flow cytometry are the factors contributing to its dominance.

Key Points: 
  • Growing demand for early diagnosis and increasing consciousness regarding the advantages of cell-based flow cytometry are the factors contributing to its dominance.
  • The cell-based flow cytometry technology is mainly used in drug discovery for the physiological significance of the results.
  • In the market for products & services, the reagents & consumables segment has the most significant market share.
  • Moreover, higher sensitivity, easy-to-use analysis, and quick outcomes associated with flow cytometry will also likely drive the flow cytometers' global market growth soon.

Data Published in Nature Communications Demonstrate the Power of Fluidigm’s CyTOF and Imaging Mass Cytometry Technologies to Transform Cancer Drug Discovery and Enable New Precision Medicine Approaches in Clinical Oncology

Retrieved on: 
Thursday, May 6, 2021

These analyses demonstrated that mass cytometry-based phenotypic footprints captured distinct features not detected using typical genetic and genomic evaluations.

Key Points: 
  • These analyses demonstrated that mass cytometry-based phenotypic footprints captured distinct features not detected using typical genetic and genomic evaluations.
  • \xe2\x80\x9cIntegrating phenotypic data with molecular and drug response data from the same xenografts, we found that phenotypic heterogeneity at the cellular level is a critical determinant of drug response.
  • This was really key to expanding our understanding of how specific cell phenotypes are spatially distributed and their clinical relevance.
  • For more information, visit fluidigm.com .\nFluidigm, the\xc2\xa0Fluidigm\xc2\xa0logo, Advanta, CyTOF, Imaging Mass Cytometry, and IMC are trademarks and/or registered trademarks of\xc2\xa0Fluidigm Corporation\xc2\xa0in\xc2\xa0the United States\xc2\xa0and/or other countries.

Cytek Biosciences Receives CE Marking on Its Northern Lights (NL)-CLC Platform

Retrieved on: 
Wednesday, September 16, 2020

Cytek Biosciences Inc. , a leading provider of cell analysis instrumentation and solutions, today announced that its Cytek Northern Lights flow cytometer (product certification abbreviation NL-CLC) has received CE Marking under the European Union In Vitro Diagnostic Medical Devices Directive (IVDD) 98/79/EC.

Key Points: 
  • Cytek Biosciences Inc. , a leading provider of cell analysis instrumentation and solutions, today announced that its Cytek Northern Lights flow cytometer (product certification abbreviation NL-CLC) has received CE Marking under the European Union In Vitro Diagnostic Medical Devices Directive (IVDD) 98/79/EC.
  • Cytek Northern Lights has been designed, manufactured and tested in accordance with Cytek design controls, quality systems and applicable verification and validation procedures and protocols that are reflective of flow cytometry in vitro diagnostic medical devices.
  • Achieving CE Marking and gaining European market access is more proof of our commitment to redefining what is possible in flow cytometry and offering a total solution for clinical applications, noted Dr. Wenbin Jiang, CEO of Cytek Biosciences.
  • Cytek Northern Lights offers a value-added package with capabilities that go beyond flow cytometry systems with a much higher price tag.

Worldwide Flow Cytometry Industry to 2025 - Impact of COVID-19 on the Market

Retrieved on: 
Friday, August 21, 2020

DUBLIN, Aug. 21, 2020 /PRNewswire/ -- The "Flow Cytometry Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 21, 2020 /PRNewswire/ -- The "Flow Cytometry Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • The global flow cytometry market grew at a CAGR of around 8% during 2014-2019.
  • Furthermore, the widespread adoption of stem cell therapy is also enhancing the utilization of flow cytometry.
  • Looking forward, the publisher expects the global flow cytometry market to continue its moderate growth during the next five years.